Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Accepts Three Approval Pathways, Defers Registry For High-Risk Devices

Executive Summary

The Australian government plans to introduce a series of regulatory reforms for devices and drugs over a period of three years, including moves to speed up access to innovative devices and to better leverage assessments by overseas regulators. The changes may include some recovery of costs from industry.

You may also be interested in...



Australia To Make Access To Unauthorized Products Faster And Less Bothersome

New proposals by Australia’s Therapeutic Goods Administration include developing a list of unauthorized medical devices that could be made available to patients faster and more easily. A decision to include a product on the list would not be appealable, the TGA says.

Australia Steps Up Priority Review And Faster Assessment Plans

The Therapeutic Goods Administration is seeking feedback on proposals for a priority-review pathway and a system for designating Australian conformity assessment bodies. Both efforts promise to speed products to market and might also involve new fees for industry.

Australia’s 'Unrealistic' Randomized Controlled Trial Proposal Comes Under Fire

Industry is not entirely happy with the Therapeutic Goods Administration’s proposed guidelines on clinical evidence requirements.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel